SCHEMBL810559

SCHEMBL810559

FC(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)CI

nearest known ligand 0.38

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.38
THRB P10828 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4337670 1.00 LMNA (0.38) LMNATHRB
SCHEMBL25685789 1.00 LMNA (0.38) LMNATHRB
SCHEMBL20848204 1.00 LMNA (0.38) LMNATHRB
SCHEMBL4337634 1.00 LMNA (0.38) LMNATHRB
SCHEMBL28597147 0.97 LMNA (0.33) LMNA
SCHEMBL4182547 0.87
SCHEMBL10300018 0.87
SCHEMBL25685341 0.80
SCHEMBL3022678 0.79
SCHEMBL14780804 0.78 LMNA (0.32) LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-113134210-A Fire extinguishing article and method for manufacturing same 南京同宁新材料研究院有限公司 2021-07-20 CN claimed
EP-0614874-B1 Process for the preparation of halogenated esters of carboxylic or dicarboxylic acids ATOCHEM ELF SA (FR) 1999-01-27 EP claimed
WO-2023119165-A1 COMPOUNDS COMPRISING A PLURALITY OF SILSESQUIOXANE GROUPS FOR FORMING A PATTERNING COATING AND DEVICES INCORPORATING SAME OTI LUMIONICS INC. (CA) 2023-06-29 WO disclosed
CN-115872833-A Synthesis method of deuterated perfluorohexyl n-octane 江苏正大清江制药有限公司 2023-03-31 CN disclosed
CN-115703693-A Novel synthesis method of perfluorohexyl n-octane 江苏正大清江制药有限公司 2023-02-17 CN disclosed
EP-3645634-B1 FLUORINATED ESTER COMPOUND ADDITIVES FOR ARCHITECTURAL COATINGS CHEMOURS CO FC LLC (US) 2022-12-28 EP disclosed
US-11518894-B2 Fluorinated ester compound additives for architectural coatings THE CHEMOURS COMPANY FC, LLC (US) 2022-12-06 US disclosed
WO-2022097043-A1 SILICON-CONTAINING COMPOUNDS FOR FORMING A PATTERNING COATING AND DEVICES INCORPORATING SAME OTI LUMIONICS INC. (CA) 2022-05-12 WO disclosed
CN-113134210-A Fire extinguishing article and method for manufacturing same 南京同宁新材料研究院有限公司 2021-07-20 CN disclosed
EP-3269395-A1 AMINOALCOHOL LIPIDOIDS AND USES THEREOF Massachusetts Institute Of Technology (US) 2018-01-17 EP disclosed
EP-2389399-A2 FUNCTIONALIZED POLYURETHANE RESIN, METHOD FOR THE PRODUCTION THEREOF, AND USE THEREOF Construction Research & Technology GmbH (DE) 2011-11-30 EP disclosed
US-20090198000-A1 Liquid fluorine-containing and two-component compositions for the surface treatment of mineral and non-mineral substrates EVONIK DEGUSSA GMBH (DE) 2009-08-06 US disclosed
EP-2085442-A1 Compounds containing fluoride with improved surface characteristics Evonik Degussa GmbH (DE) 2009-08-05 EP disclosed
US-20090054588-A1 Fluoride-modified additive for cementitious products, process for its preparation and use thereof CONSTRUCTION RESEARCH & TECHNOLOGY GMBH (DE) 2009-02-26 US disclosed
WO-2008040428-A2 FUNCTIONALIZED POLYURETHANE RESIN, METHOD FOR THE PRODUCTION THEREOF, AND USE THEREOF CONSTRUCTION RESEARCH & TECHNOLOGY GMBH (DE) 2008-04-10 WO disclosed
US-6780855-B2 TREATING A PATIENT SUFFERING FROM AN ESTROGEN DEPENDENT-DISEASE SCHERING AKTIENGESELLSCHAFT (DE) 2004-08-24 US disclosed
US-20030069434-A1 11BETA-HALOGEN-7ALPHA-SUBSTITUTED ESTRATRIENES, METOD FOR PRODUCING PHARMACEUTICAL PREPARATIONS CONTAINING SAID 11BETA-HALOGEN-7ALPHA- SUBSTITUTED ESTRATRIENES AND USE OF THE SAME FOR PRODUCING MEDICAMENTS BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2003-04-10 US disclosed
EP-1042355-B1 11BETA-HALOGEN-7ALPHA-SUBSTITUTED ESTRATRIENES, METHOD FOR PRODUCING PHARMACEUTICAL PREPARATIONS CONTAINING SAID 11BETA-HALOGEN-7ALPHA-SUBSTITUTED ESTRATRIENES AND USE OF THE SAME FOR PRODUCING MEDICAMENTS SCHERING AG (DE) 2003-02-12 EP disclosed
EP-1042355-A1 11BETA-HALOGEN-7ALPHA-SUBSTITUTED ESTRATRIENES, METHOD FOR PRODUCING PHARMACEUTICAL PREPARATIONS CONTAINING SAID 11BETA-HALOGEN-7ALPHA-SUBSTITUTED ESTRATRIENES AND USE OF THE SAME FOR PRODUCING MEDICAMENTS Schering Aktiengesellschaft (DE) 2000-10-11 EP disclosed
WO-1999033855-A1 11β-HALOGEN-7α-SUBSTITUTED ESTRATRIENES, METHOD FOR PRODUCING PHARMACEUTICAL PREPARATIONS CONTAINING SAID 11β-HALOGEN-7α-SUBSTITUTED ESTRATRIENES AND USE OF THE SAME FOR PRODUCING MEDICAMENTS SCHERING AKTIENGESELLSCHAFT (DE) 1999-07-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030069434-A1 11BETA-HALOGEN-7ALPHA-SUBSTITUTED ESTRATRIENES, METOD FOR PRODUCING PHARMACEUTICAL PREPARATIONS CONTAINING SAID 11BETA-HALOGEN-7ALPHA- SUBSTITUTED ESTRATRIENES AND USE OF THE SAME FOR PRODUCING MEDICAMENTS CYP19A1, HSD17B11, NR5A1 LMNA 4408/4885THRB 254/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.